

Name: Dr Seema Kumari

Position & Affiliation: PhD Student, Medical Oncologist

The Westmead Institute for Medical Research, Westmead, NSW, Australia.

Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.



Full Reference: Seema Kumari, Tania Moujaber, Brian Gloss, Ida Madsen, Bo Gao, Pamela Provan for the INOVATe Investigators, Sivatharsny Srirangan, Natalie Bouantoun, Catherine J Kennedy, Nadia Traficante for the Australian Ovarian Cancer Study Group, Michael Friedlander, Alison Brand, Charlie Gourley, Dale W Garsed, David DL Bowtell, Rosemary L Balleine, Paul R Harnett, Anna DeFazio, 'Biomarkers to Predict Chemotherapy Response in Low-Grade Serous Ovarian Carcinoma'.

Conference/Meeting Name: ESMO Gynaecological Cancers Congress 2024

Location (city, state, country): Florence, Firenze province, Italy

Dates: 20/6/2024- 22/6/2024

Presentation Type: Poster



Amazing conference- ESMO gynaecological cancers congress 2024 in this beautiful city of Florence. Learnt from the world leaders in gynaecological-oncology and also had the opportunity to share some of my PhD results thanks to Sydney Cancer Partners travel grant.

The ESMO Gynaecological Cancers Congress 2024 was a prominent gathering focused on advancing knowledge and collaboration in the field of gynaecological oncology. The congress brought together a diverse range of attendees, including researchers, clinicians, oncologists, and allied healthcare professionals dedicated to improving outcomes for patients with gynaecological cancers. The theme of the congress revolved around recent advancements in diagnosis, treatment modalities, and patient care strategies for gynaecological cancers. Key topics discussed included innovative therapies, personalized medicine approaches, and multidisciplinary care models.

The congress hosted a notable lineup of invited speakers who are leaders in the field including prominent researchers and clinicians such as Dr Ana Oaknin, Dr Mansoor Raza Mirza, Dr Antonio González-Martín, Dr Brad Monk and Prof Susana Banerjee who presented cutting-edge research findings, clinical trial results, and practical insights into the management of gynaecological cancers. The keynote speakers were Prof Domenica Lorusso and Prof GIOVANNI Scambia.

Key areas of discussion/presentation included practice-changing progress in the treatment of gynaecological cancers, recent developments with PARP inhibitors to treat ovarian cancer, state-of-the-art in the diagnosis and management of cervical and endometrial cancers, the evolving role of surgery and HIPEC in gynaecological cancers, and novel therapeutic strategies for rare gynaecological cancers.

The learning objectives and outcomes of this congress included:

- Established and emerging biomarkers applicable for precision medicine and treatment selection in patients with gynaecological cancers.
- Updates on state-of-the-art expert management of patients with gynaecological cancers.
- The scientific advances in profiling, risk stratification and innovative therapies for the optimal care of patients with gynaecological cancers.

I had the opportunity to speak to Prof Susana Banerjee and gain her insights into the management of patients with low grade serous ovarian cancer which is the topic of my PhD research. During the poster session, I was approached by researchers and students with similar interests, and we ended up sharing our research methodologies and techniques. For instance, I had the opportunity to network with another Australia-based researcher who is also working on ovarian cancer cell lines, and I could potentially reach out to her in near future for collaboration.

The knowledge and skills gained from the ESMO Gynaecological Cancers Congress 2024 will directly benefit my current research on low grade serous ovarian cancer by enhancing research methodologies, providing updated treatment insights, promoting multidisciplinary approaches, and fostering collaborations.

My personal highlight of this congress was when Prof Susana Banerjee during her talk on low grade serous ovarian cancer presented a slide which was referenced from my PhD supervisors Dr Tania Moujaber and Prof Anna DeFazio's paper. This was a moment of pride for me, and I felt truly privileged to be a part of the gynae-oncology research team at the Westmead Institute for Medical Research.

The ESMO Gynaecological Cancers Congress 2024 provided a platform for knowledge exchange, networking, and collaboration among experts, aiming to drive forward the field and ultimately improve outcomes for patients affected by gynaecological cancers which aligns with the aims of Sydney Cancer Partners.

Finally, a visit to the world-famous Duomo and Uffizi Galleries was like an 'icing on the cake' in this trip. I would like to sincerely thank Sydney Cancer Partners for supporting my attendance to this educational meeting.